Affinage

YY1AP1

YY1-associated protein 1 · UniProt Q9H869

Length
796 aa
Mass
87.9 kDa
Annotated
2026-06-11
100 papers in source corpus 4 papers cited in narrative 5 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 4/4 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

YY1AP1 is a nuclear transcriptional co-activator that couples the YY1 transcription factor to chromatin remodeling machinery to control cell proliferation and lineage differentiation (PMID:14744866, PMID:27939641). It binds YY1 directly through two YY1-binding regions and carries an intrinsic transactivation domain mapped to residues 260–345, enhancing transcription from YY1-responsive promoters (PMID:14744866). YY1AP1 is a component of the INO80 chromatin remodeling complex, and its loss in vascular smooth muscle cells drives cell cycle arrest with p21/CDKN1A upregulation and impairs TGF-β-driven smooth muscle differentiation; biallelic loss-of-function mutations in YY1AP1 cause Grange syndrome and a fibromuscular dysplasia-like vascular disease (PMID:27939641). In EpCAM+AFP+ hepatocellular carcinoma, YY1AP1 cooperates with YY1 to remodel the chromatin landscape and activate stemness gene programs, and its silencing eliminates oncogene addiction, triggering apoptosis and suppressing tumor growth (PMID:25597408). Beyond these contexts, the upstream signals regulating YY1AP1 activity remain largely uncharacterized in the available corpus.

Mechanistic history

Synthesis pass · year-by-year structured walk · 5 steps
  1. 2004 High

    Established that YY1AP1 is a direct physical partner and co-activator of YY1, defining its core molecular function as transcriptional enhancement rather than an independent activity.

    Evidence Yeast two-hybrid, GST pull-down, co-IP, immunostaining, and luciferase reporter assays, with transactivation domain mapped to aa 260–345

    PMID:14744866

    Open questions at the time
    • Does not identify the chromatin or co-factor machinery recruited by YY1AP1
    • Endogenous target genes not defined
    • Mechanism of transactivation by the 260–345 domain unresolved
  2. 2004 Medium

    Defined YY1AP1 as a ubiquitously expressed nuclear protein, fixing its compartment of action.

    Evidence Northern blot, immunostaining, 5'-RACE/cDNA cloning placing the gene at 1q21.3 encoding a 750-aa protein

    PMID:14744866

    Open questions at the time
    • Does not address tissue-specific functional roles despite ubiquitous expression
    • No sub-nuclear localization detail
  3. 2015 High

    Showed that YY1AP1, with YY1, reprograms chromatin to sustain stemness programs in a hepatocellular carcinoma subtype, linking the co-activator to oncogenic cell-state maintenance.

    Evidence siRNA knockdown, in vitro apoptosis assays, in vivo xenograft suppression, and chromatin/transcriptomic landscape analysis in EpCAM+AFP+ HCC

    PMID:25597408

    Open questions at the time
    • Specific stemness target genes and direct chromatin binding sites not enumerated
    • Does not define the remodeling complex mediating the chromatin changes in this context
  4. 2016 High

    Identified YY1AP1 as a subunit of the INO80 chromatin remodeling complex and as a disease gene, connecting its molecular partnership to proliferation control, smooth muscle differentiation, and human vascular pathology.

    Evidence Exome sequencing of patient families, reciprocal co-IP with INO80 components, cellular fractionation, siRNA knockdown in vascular smooth muscle cells with cell cycle, p21, and TGF-β differentiation assays

    PMID:27939641

    Open questions at the time
    • Structural position of YY1AP1 within INO80 not defined
    • Mechanistic link between INO80 membership and YY1 co-activation not directly resolved
    • How p21 upregulation is triggered mechanistically unclear
  5. 2019 Low

    Raised the possibility that YY1AP1 nuclear activity is post-translationally regulated by AKT signaling, addressing how the co-activator's localization might be controlled.

    Evidence Western blot of phospho-YY1AP1, immunofluorescence of nuclear localization, and IGF1 pharmacological rescue within a SRC/AKT/STAT3/YY1AP1 axis in renal carcinoma cells

    PMID:31354472

    Open questions at the time
    • Phosphorylation sites and direct kinase not identified
    • Pathway placement of YY1AP1 is indirect
    • Functional consequence of altered phosphorylation on YY1 co-activation not tested

Open questions

Synthesis pass · forward-looking unresolved questions
  • How INO80 membership, YY1 co-activation, and post-translational regulation integrate to select target genes in a given cell type remains unresolved.
  • No direct genome-wide binding map for YY1AP1
  • Structural basis of complex assembly unknown
  • Upstream signals controlling context-specific activity uncharacterized

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 2 GO:0140097 catalytic activity, acting on DNA 1
Localization
GO:0005634 nucleus 3
Pathway
R-HSA-4839726 Chromatin organization 2 R-HSA-74160 Gene expression (Transcription) 1
Partners
YY1
Complex memberships
INO80 chromatin remodeling complex

Evidence

Reading pass · 5 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2004 YY1AP1 (YY1AP) was identified as a direct binding partner and co-activator of the YY1 transcription factor. Yeast two-hybrid screening, co-immunoprecipitation, and GST pull-down assays showed that YY1AP contains two YY1-binding regions. YY1AP co-localizes with YY1 in the nucleus and enhances transcriptional activation from a YY1-responsive promoter. The transactivation domain of YY1AP was mapped to amino acids 260–345. Yeast two-hybrid screen, GST pull-down assay, co-immunoprecipitation, immunostaining, luciferase reporter assay The Journal of Biological Chemistry High 14744866
2004 YY1AP1 protein localizes to the nucleus and is ubiquitously expressed across human tissues and cancer cell lines. The chromosomal gene maps to chromosome 1q21.3 and encodes a 750 amino acid protein. Northern blot, immunostaining, 5'-RACE and cDNA cloning The Journal of Biological Chemistry Medium 14744866
2015 YY1AP1 cooperates with YY1 to alter the chromatin landscape and activate transcription of stemness regulators in EpCAM+AFP+ hepatocellular carcinoma (HCC). YY1AP1 silencing eliminated oncogene addiction, triggered massive apoptosis in vitro, and suppressed tumor growth in vivo. YY1AP1 expression is required for maintenance of stem cell features in this HCC subtype. siRNA knockdown, in vitro apoptosis assays, in vivo xenograft tumor suppression, transcriptomic/chromatin landscape analysis, integrative genomics (copy number + expression) Oncogene High 25597408
2016 Loss-of-function mutations in YY1AP1 cause Grange syndrome and a fibromuscular dysplasia-like vascular disease. YY1AP1 localizes to the nucleus and is a component of the INO80 chromatin remodeling complex. Loss of YY1AP1 in vascular smooth muscle cells causes cell cycle arrest with decreased proliferation, increased p21/WAF/CDKN1A levels, and disrupts TGF-β-driven differentiation of smooth muscle cells. Exome sequencing, cellular fractionation/nuclear localization assay, co-immunoprecipitation with INO80 complex components, siRNA knockdown in vascular smooth muscle cells, cell cycle and proliferation assays, p21 protein level measurement, TGF-β differentiation assay American Journal of Human Genetics High 27939641
2019 Nobiletin treatment increases phosphorylation of YY1AP1 and decreases its nuclear localization in renal carcinoma cells, as part of a signaling axis involving SRC/AKT/STAT3/YY1AP1. IGF1 reversed the nobiletin-induced changes in phospho-YY1AP1 levels and antitumor effects, suggesting YY1AP1 activity is regulated by AKT signaling in this context. Western blot (phospho-YY1AP1), immunofluorescence (nuclear localization), pharmacological rescue with IGF1, in vivo xenograft Frontiers in Pharmacology Low 31354472

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 Role of YAP/TAZ in mechanotransduction. Nature 4604 21654799
2008 TEAD mediates YAP-dependent gene induction and growth control. Genes & development 2110 18579750
2016 YAP/TAZ at the Roots of Cancer. Cancer cell 1611 27300434
2017 Mechanobiology of YAP and TAZ in physiology and disease. Nature reviews. Molecular cell biology 1084 28951564
2015 The emerging roles of YAP and TAZ in cancer. Nature reviews. Cancer 968 25592648
2018 YAP/TAZ upstream signals and downstream responses. Nature cell biology 804 30050119
2014 Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. American journal of physiology. Lung cellular and molecular physiology 716 25502501
2015 Alternative Wnt Signaling Activates YAP/TAZ. Cell 597 26276632
2015 YAP and TAZ: a nexus for Hippo signaling and beyond. Trends in cell biology 494 26045258
2017 YAP regulates cell mechanics by controlling focal adhesion assembly. Nature communications 488 28504269
2018 Interplay between YAP/TAZ and Metabolism. Cell metabolism 380 30089241
2020 YAP/TAZ functions and their regulation at a glance. Journal of cell science 292 31996398
2020 YAP-mediated mechanotransduction tunes the macrophage inflammatory response. Science advances 239 33277245
2015 Disease implications of the Hippo/YAP pathway. Trends in molecular medicine 194 25702974
2016 YAP Induces Human Naive Pluripotency. Cell reports 159 26947063
2018 Skeletal cell YAP and TAZ combinatorially promote bone development. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 149 29401582
2020 Integration of Hippo-YAP Signaling with Metabolism. Developmental cell 146 32693058
2017 Glucocorticoid receptor signalling activates YAP in breast cancer. Nature communications 142 28102225
2013 YAP/TEAD-mediated transcription controls cellular senescence. Cancer research 137 23576552
2018 DNA binding partners of YAP/TAZ. BMB reports 135 29366442
2018 Crosstalk between YAP/TAZ and Notch Signaling. Trends in cell biology 130 29665979
2020 YAP and TAZ Are Not Identical Twins. Trends in biochemical sciences 126 32981815
2023 Control of stem cell renewal and fate by YAP and TAZ. Nature reviews. Molecular cell biology 123 37626124
2014 The regulation and function of YAP transcription co-activator. Acta biochimica et biophysica Sinica 118 25487920
2016 YAP-Mediated Mechanotransduction in Skeletal Muscle. Frontiers in physiology 99 26909043
2009 YAP: at the crossroad between transformation and tumor suppression. Cell cycle (Georgetown, Tex.) 97 19106601
2019 The Role of YAP and TAZ in Angiogenesis and Vascular Mimicry. Cells 89 31052445
2022 New Insights into Hippo/YAP Signaling in Fibrotic Diseases. Cells 88 35805148
2018 Multifaceted regulation and functions of YAP/TAZ in tumors (Review). Oncology reports 84 29749524
2019 YAP and TAZ Negatively Regulate Prox1 During Developmental and Pathologic Lymphangiogenesis. Circulation research 82 30582452
2019 The Emerging Role of YAP/TAZ in Tumor Immunity. Molecular cancer research : MCR 82 31308148
2019 YAP and TAZ Mediate Osteocyte Perilacunar/Canalicular Remodeling. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 80 31610061
2017 YAP/TAZ initiate and maintain Schwann cell myelination. eLife 78 28124973
2021 YAP promotes autophagy and progression of gliomas via upregulating HMGB1. Journal of experimental & clinical cancer research : CR 73 33726796
2015 YAP and TAZ Take Center Stage in Cancer. Biochemistry 72 26465056
2019 The posttranslational modifications of Hippo-YAP pathway in cancer. Biochimica et biophysica acta. General subjects 67 31306710
2023 Nuclear compression regulates YAP spatiotemporal fluctuations in living cells. Proceedings of the National Academy of Sciences of the United States of America 66 37399392
2022 Roles of YAP/TAZ in ferroptosis. Trends in cell biology 64 35701310
2023 YAP/TAZ: Molecular pathway and disease therapy. MedComm 62 37576865
2020 Concerted localization-resets precede YAP-dependent transcription. Nature communications 61 32917893
2018 Hippo-YAP/TAZ signaling in angiogenesis. BMB reports 61 29366443
2014 Hippo/YAP pathway for targeted therapy. Translational lung cancer research 61 25806284
2018 Evolution of mechanotransduction via YAP/TAZ in animal epithelia. Current opinion in cell biology 60 29477107
2019 The Roles of Hippo Signaling Transducers Yap and Taz in Chromatin Remodeling. Cells 58 31137701
2016 Loss-of-Function Mutations in YY1AP1 Lead to Grange Syndrome and a Fibromuscular Dysplasia-Like Vascular Disease. American journal of human genetics 58 27939641
2023 Mechanoepigenetic regulation of extracellular matrix homeostasis via Yap and Taz. Proceedings of the National Academy of Sciences of the United States of America 57 37216538
2021 TAZ-CAMTA1 and YAP-TFE3 alter the TAZ/YAP transcriptome by recruiting the ATAC histone acetyltransferase complex. eLife 57 33913810
2021 ABHD5 inhibits YAP-induced c-Met overexpression and colon cancer cell stemness via suppressing YAP methylation. Nature communications 56 34795238
2019 PTPN14 phosphatase and YAP promote TGFβ signalling in rheumatoid synoviocytes. Annals of the rheumatic diseases 56 30808624
2018 The Ambivalent Function of YAP in Apoptosis and Cancer. International journal of molecular sciences 56 30486435
2014 c-Abl antagonizes the YAP oncogenic function. Cell death and differentiation 56 25361080
2016 Expression and significance of Hippo/YAP signaling in glioma progression. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 54 27718125
2017 Targeting YAP in malignant pleural mesothelioma. Journal of cellular and molecular medicine 51 28470935
2017 Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues. Human pathology 51 28899737
2020 Tubule-Specific Mst1/2 Deficiency Induces CKD via YAP and Non-YAP Mechanisms. Journal of the American Society of Nephrology : JASN 50 32253273
2017 Dual roles of yes-associated protein (YAP) in colorectal cancer. Oncotarget 49 29088905
2023 LncRNA modulates Hippo-YAP signaling to reprogram iron metabolism. Nature communications 47 37080959
2023 The deubiquitinating enzyme USP19 facilitates hepatocellular carcinoma progression through stabilizing YAP. Cancer letters 47 37832781
2019 YAP and TAZ regulate cell volume. The Journal of cell biology 47 31481532
2024 FAK, vinculin, and talin control mechanosensitive YAP nuclear localization. Biomaterials 45 38547833
2021 Mechanisms of YAP/TAZ transcriptional control. Cell stress 45 34782888
2018 Enigma proteins regulate YAP mechanotransduction. Journal of cell science 45 30404826
2017 YAP and the Hippo pathway in pediatric cancer. Molecular & cellular oncology 45 28616573
2021 YAP in pancreatic cancer: oncogenic role and therapeutic strategy. Theranostics 44 33408779
2019 YAP and the Hippo pathway in cholangiocarcinoma. Journal of gastroenterology 44 30815737
2019 Nobiletin Inhibits Cell Viability via the SRC/AKT/STAT3/YY1AP1 Pathway in Human Renal Carcinoma Cells. Frontiers in pharmacology 44 31354472
2018 Hippo-yap signaling in ocular development and disease. Developmental dynamics : an official publication of the American Association of Anatomists 44 29532607
2015 Integrative genomics identifies YY1AP1 as an oncogenic driver in EpCAM(+) AFP(+) hepatocellular carcinoma. Oncogene 43 25597408
2015 Expression of Yes-associated protein (YAP) in metastatic breast cancer. International journal of clinical and experimental pathology 43 26617849
2019 Yes-associated protein (YAP) and transcriptional coactivator with a PDZ-binding motif (TAZ): a nexus between hypoxia and cancer. Acta pharmaceutica Sinica. B 42 32642404
2004 YY1AP, a novel co-activator of YY1. The Journal of biological chemistry 42 14744866
2020 H3K27me3-mediated PGC1α gene silencing promotes melanoma invasion through WNT5A and YAP. The Journal of clinical investigation 41 31929186
2022 YAP/TAZ in Bone and Cartilage Biology. Frontiers in cell and developmental biology 39 35059398
2021 Concurrent YAP/TAZ and SMAD signaling mediate vocal fold fibrosis. Scientific reports 39 34188130
2022 Combined role for YAP-TEAD and YAP-RUNX2 signalling in substrate-stiffness regulation of cardiac fibroblast proliferation. Biochimica et biophysica acta. Molecular cell research 38 35905788
2021 YAP and endothelin-1 signaling: an emerging alliance in cancer. Journal of experimental & clinical cancer research : CR 38 33422090
2018 Repurposing of Drugs Targeting YAP-TEAD Functions. Cancers 38 30223434
2017 YAP promotes tumorigenesis and cisplatin resistance in neuroblastoma. Oncotarget 38 28415761
2020 TBK1 regulates YAP/TAZ and fibrogenic fibroblast activation. American journal of physiology. Lung cellular and molecular physiology 34 32159970
2022 CD146 increases stemness and aggressiveness in glioblastoma and activates YAP signaling. Cellular and molecular life sciences : CMLS 33 35790583
2021 Targeting the YAP/TAZ Pathway in Uveal and Conjunctival Melanoma With Verteporfin. Investigative ophthalmology & visual science 33 33798262
2018 YAP and TAZ are distinct effectors of corneal myofibroblast transformation. Experimental eye research 33 30578787
2023 YAP at the progression of inflammation. Frontiers in cell and developmental biology 32 37397250
2019 MK5 Regulates YAP Stability and Is a Molecular Target in YAP-Driven Cancers. Cancer research 32 31578200
2022 The biology of YAP in programmed cell death. Biomarker research 31 35606801
2017 YAP and WWTR1: New targets for skin cancer treatment. Cancer letters 31 28279717
2024 Biomimetic nanodrug targets inflammation and suppresses YAP/TAZ to ameliorate atherosclerosis. Biomaterials 28 38359507
2024 YAP condensates are highly organized hubs. iScience 28 38784009
2022 Hippo-Yap Signaling Maintains Sinoatrial Node Homeostasis. Circulation 28 36317529
2015 Yes-associated protein (YAP) expression is involved in epithelial-mesenchymal transition in hepatocellular carcinoma. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 28 26254048
2023 Tripterygium wilfordii derivative celastrol, a YAP inhibitor, has antifibrotic effects in systemic sclerosis. Annals of the rheumatic diseases 26 37328193
2021 Yes-Associated Protein (Yap) Is Up-Regulated in Heart Failure and Promotes Cardiac Fibroblast Proliferation. International journal of molecular sciences 26 34200497
2019 A brief review: some compounds targeting YAP against malignancies. Future oncology (London, England) 26 31066301
2021 YAP and TAZ Mediators at the Crossroad between Metabolic and Cellular Reprogramming. Metabolites 25 33800464
2023 Nuclear Import and Export of YAP and TAZ. Cancers 22 37894323
2022 PDE4D binds and interacts with YAP to cooperatively promote HCC progression. Cancer letters 22 35597479
2022 YAP Activation in Promoting Negative Durotaxis and Acral Melanoma Progression. Cells 22 36428972
2021 Hippo-YAP signaling in digestive system tumors. American journal of cancer research 22 34249412
2024 DNMT3A Cooperates with YAP/TAZ to Drive Gallbladder Cancer Metastasis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 21 38380551
2024 STC1 competitively binding βPIX enhances melanoma progression via YAP nuclear translocation and M2 macrophage recruitment through the YAP/CCL2/VEGFA/AKT feedback loop. Pharmacological research 21 38768671

Missed literature

Know a paper Affinage missed for YY1AP1? Flag it for the maintainers and the community.

No submissions yet.